American journal of clinical pathology
-
Am. J. Clin. Pathol. · Apr 2012
Pathology consultation on the laboratory evaluation of thrombophilia: when, how, and why.
Venous thromboembolism (VTE) results from the interaction of the Virchow triad (venous stasis, endothelial injury, and hypercoagulability). Risk factors for increased hypercoagulability, or thrombophilia, include activated protein C resistance/factor V Leiden, the prothrombin G20210A mutation, deficiencies of the natural anticoagulants (antithrombin, proteins C and S), antiphospholipid antibodies, hyperhomocysteinemia, and increased factor VIII activity. Not all patients with VTE need to be tested for such risk factors, but patients with thrombophilia should be evaluated for all possibilities to better estimate risk. At the same time, testing should be patient-specific because assay results are affected by preanalytic variables, including thrombosis and anticoagulant therapy.
-
Addenda are typically used to report results of additional studies that are delayed relative to histopathologic studies. However, the frequency and pattern of use of addenda have not been previously reported. We studied the dynamics of addenda creation within the same month at 5-year intervals during a 15-year period at our institution. ⋯ Cases with addenda increased from 0.9% in 1993 to 8.6% in 2008. In 5.6% of addenda, there was information that might have been better reported in an amendment, suggesting that criteria for amendments need to be universally implemented. Charting trends and types of addenda offered opportunities for quality improvement by identifying weaknesses in the workflow organization of the laboratory.
-
Am. J. Clin. Pathol. · Apr 2012
A massive transfusion protocol incorporating a higher FFP/RBC ratio is associated with decreased use of recombinant activated factor VII in trauma patients.
We implemented a protocol incorporating a higher fresh frozen plasma (FFP)/RBC ratio for the management of trauma patients requiring massive transfusion in 2007. This study aims to identify issues that affected the effective deployment of the massive transfusion protocol (MTP) and compare outcome variables with a historic cohort. ⋯ Compared with the historic cohort, the 1:1-1:2 group received significantly fewer blood components and did not require rescue rFVIIa. An MTP incorporating a higher FFP/RBC ratio of 1:1 to 1:2 is associated with decreased use of blood components and may obviate the need for rFVII.